EMERALD Study will investigate safety and efficacy of engineered macrophage cell therapy in patients with decompensated liver cirrhosis LONDON and EDINBURGH, Scotland, June 27, 2024 /PRNewswire/ — Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company…
Month: June 2024
EMERALD Study will investigate safety and efficacy of engineered macrophage cell therapy in patients with decompensated liver cirrhosis LONDON and EDINBURGH, Scotland, June 27, 2024 /PRNewswire/ — Resolution Therapeutics Limited (“Resolution”), a clinical-stage biopharmaceutical company…
WILLINGTON, England, June 27, 2024 /PRNewswire/ — Bionical Solutions, a leading provider of technology enabled engagement and healthcare services to global pharmaceutical, biotech, healthcare companies and the NHS, today announced the appointment of Tom Tacon as Business Unit Director of…
WILLINGTON, England, June 27, 2024 /PRNewswire/ — Bionical Solutions, a leading provider of technology enabled engagement and healthcare services to global pharmaceutical, biotech, healthcare companies and the NHS, today announced the appointment of Tom Tacon as Business Unit Director of…
SLIEMA, Malta, 27 juni, 2024 /PRNewswire/ — Soft2Bet är glada att tillkännage lanseringen av “Soft2Bet Invest”, sin iGaming-innovationsfond som kommer att ge ekonomiskt och affärsmässigt stöd till iGaming- och casual gaming-entreprenörer som har samma drivkraft för innovation och…
SLIEMA, Malta, 27 juni, 2024 /PRNewswire/ — Soft2Bet är glada att tillkännage lanseringen av “Soft2Bet Invest”, sin iGaming-innovationsfond som kommer att ge ekonomiskt och affärsmässigt stöd till iGaming- och casual gaming-entreprenörer som har samma drivkraft för innovation och…
New results from Medivir’s Phase 1b / 2a open label trial of fostrox + Lenvima® show great promise treating second-line hepatocellular carcinoma (HCC) patients, an extremely hard to treat population Fostrox + Lenvima® achieved a 24% overall response rate (ORR) and estimated median time to…
New results from Medivir’s Phase 1b / 2a open label trial of fostrox + Lenvima® show great promise treating second-line hepatocellular carcinoma (HCC) patients, an extremely hard to treat population Fostrox + Lenvima® achieved a 24% overall response rate (ORR) and estimated median time to…
OSLO, Norway, June 27, 2024 /PRNewswire/ — Akastor ASA invites investors and analysts to a webcast presentation of first quarter 2024 financial results on Thursday 11 July 2024. Date and time: Thursday 11 July 2024 at 15:00 CET Presenters: Akastor – Karl Erik Kjelstad, CEO and Øyvind…
OSLO, Norway, June 27, 2024 /PRNewswire/ — Akastor ASA invites investors and analysts to a webcast presentation of first quarter 2024 financial results on Thursday 11 July 2024. Date and time: Thursday 11 July 2024 at 15:00 CET Presenters: Akastor – Karl Erik Kjelstad, CEO and Øyvind…
